AI in Pharmacovigilance Market Size, Share & Trends Analysis Report by Component (Software, Services), Technology, Deployment Mode, Process Stage, Application, End-users and Geography (North America, Europe, Asia Pacific, Middle East, Africa and South America) – Global Industry Data, Trends and Forecasts, 2026–2035
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
AI in Pharmacovigilance Market Size, Share, and Growth
The global AI in pharmacovigilance market is exhibiting strong growth, with an estimated value of USD 0.4 billion in 2025 and USD 1.9 billion by 2035, achieving a CAGR of 17.1%, during the forecast period.
“Oracle Argus has been the gold standard in pharmacovigilance for decades,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “Working with organizations like PrimeVigilance we are building on that excellence to deliver cloud-based, AI-enabled solutions that improve safety monitoring for the benefit of the industry and the patients waiting for potentially lifesaving solutions.”
AI-powered automation in adverse event processing and case intake is enhancing the efficiency, accuracy, and regulatory compliance of pharmacovigilance. For instance, in March 2025, IQVIA emphasized the use of AI in pharmacovigilance, while leveraging integrated people, process and technology governance to enhance drug safety, regulatory compliance and end-to-end PV workflows. This is enabling rapid, precise detection of safety signals and lowering of manual PV task load and improving regulatory compliance throughout drug safety systems.
Moreover, a cloud-based AI pharmacovigilance ecosystem is enhancing real-time safety monitoring, signal detection, and predictive drug safety insights. For instance, in September 2025, Oracle's pharmacovigilance technology emphasizes integrated Safety One, real-world data, health data intelligence, and OCI AI capabilities for precision drug safety management. This is enabling faster, data-driven pharmacovigilance decisions through continuous safety surveillance, earlier risk detection, and improved regulatory compliance.
Adjacent growth opportunities for the global AI in pharmacovigilance market include AI-powered clinical trial analytics, real-world evidence (RWE) platforms, healthcare data interoperability solutions, AI-driven regulatory technology (RegTech), and digital therapeutics with post-market safety monitoring. This market will harness the common AI, cloud, and data integration attributes to boost drug development, compliance, and patient safety. The pharmacovigilance value chain is seeing continued commercial expansion and innovation through the addition of neighboring health-care AI value chains.
AI in Pharmacovigilance Market Dynamics and Trends
Driver: Human-Led Artificial Intelligence Platforms Accelerating Pharmacovigilance Workflow Efficiency Across Drug Development
- The advancement of the use of human-powered AI platforms is accelerating the growth of AI in pharmacovigilance market by providing automated handling of adverse events, literature review and literature screening, identification of signals, and safety documentation while retaining expertise for regulatory compliance and operational efficiency.
- This blended solution ensures data quality, audit readiness and better decision making, while meeting regulatory expectations. The growing volume of data in global clinical development is driving the shift toward AI platforms that easily connect research, regulatory, and safety efforts, thereby enhancing operational scalability and boosting product development.
- For instance, in May 2026, Parexel introduced ParexelAI, a suite of AI tools that are being integrated throughout clinical development and pharmacovigilance workflows that cut down on the time spent reviewing safety literature by 20%, while providing human experts with enhanced oversight of the processes.
- The use of AI in the pharmaceutical industry is rapidly gaining momentum, making it easier to scale, comply with regulation, and operate the pharmacovigilance function in a more efficient manner.
Restraint: Regulatory Validation Requirements Continue Limiting Rapid Deployment of Autonomous AI Pharmacovigilance Systems
- The current regulatory requirements for validation, transparency, explain ability, and auditability still hinder the widespread use of autonomous AI in pharmacovigilance. Global health authorities demand pharmacovigilance systems to be capable of performing consistently, be validated, have documented decision-making, and be able to be traced across their life cycle to a reliable quality control.
- Many advanced AI models, especially generative AI and deep learning algorithms are complex black-box systems with a regulatory validation challenge. These restrictions add to the difficulty of ensuring that AI-based safety decisions are accepted by regulators, and that automated pharmacovigilance processes are approved.
- Increase in the costs of implementation and delays in global regulatory adoption due to pharmaceutical companies needing to spend significant resources on governance, risk management, validation, and continuous monitoring before deploying AI in pharmacovigilance.
- Regulatory validation complexity continues to moderate the pace of AI adoption despite strong technological advancements.
Opportunity: Growing Adoption of Intelligent Pharmacovigilance Platforms Across Contract Research Organizations Globally
- AI-enabled pharmacovigilance platforms are becoming more common among contract research organizations to provide technology-driven, scalable safety services to pharmaceutical and biotechnology companies. With the growth of pharmacovigilance outsourcing, CROs are focusing on intelligent automation, cloud-based safety platforms, predictive analytics, and AI-powered case management to optimize operations and cut costs.
- These sophisticated features help service providers to scale with the increasing number of adverse events, enhance adherence to global regulations and provide technology-driven patient safety solutions.
- For instance, in April 2026, Parexel has acquired Vitrana to bolster its AI-powered end-to-end pharmacovigilance platform, with a focus on improving patient safety operations through automation, accuracy, regulatory compliance, and workflow efficiency.
- The global AI-driven pharmacovigilance outsourcing market is experiencing substantial growth opportunities for technology service providers and CROs.
Key Trend: Intelligent End-to-End Pharmacovigilance Platforms Integrating AI, Automation, and Advanced Analytics Capabilities
- The rapid evolution of comprehensive AI-powered pharmacovigilance platforms that combine literature monitoring, adverse event processing, regulatory reporting, natural language processing, predictive analytics, and cloud-based workflow orchestration within a single ecosystem is a significant market trend. Pharmaceutical companies are increasingly replacing isolated automation tools with integrated AI platforms that manage the complete pharmacovigilance lifecycle.
- They provide a better operational visibility, decrease manual effort, enhance regulatory compliance, and offer real-time analytics to manage safety proactively, and they can integrate with existing safety databases and enterprise systems.
- For instance, in July 2025, EVERSANA introduced ORCHESTRATE PV, an AI-driven platform developed in collaboration with Quantiphi and Oracle, which streamlines and automates pharmacovigilance processes, saving time and human effort.
- Integrated AI pharmacovigilance ecosystems are shaping the future of drug safety by providing intelligent and end-to-end workflow automation and predictive safety management.
AI in Pharmacovigilance Market Analysis and Segmental Data
Adverse Event Detection and Reporting Dominate Global AI in Pharmacovigilance Market
- The adverse event detection and reporting segment dominates the global AI in pharmacovigilance market as it plays a crucial role in maintaining drug safety throughout the product lifecycle. Pharmaceutical firms receive millions of individual case safety reports (ICSRs) from clinical trial studies, healthcare providers, patients, scientific literature, electronic health records and regulatory databases.
- AI-powered tools, such as machine learning and natural language processing, are used for automated case intake, detection of adverse events using both structured and unstructured data, prioritization based on severity, and efficient medical coding and regulatory reporting. These features can drastically cut down on manual effort, cut down on reporting errors and speed up case processing.
- The expanding regulatory demands for timely adverse event reporting, combined with the rising amount of real-world safety data, have fostered rampant adoption of AI solutions for adverse event detection and reporting across the pharmaceutical industry.
- AI-based adverse event detection and reporting are helping to make faster safety decisions, enhance regulatory compliance, and improve overall pharmacovigilance efficiencies.
North America Leads Global AI in Pharmacovigilance Market Demand
- North America leads the AI in pharmacovigilance market is due to the presence of leading pharmaceutical companies, AI technology providers, and contract research organizations is accelerating the adoption of AI-powered pharmacovigilance platforms for advanced drug safety monitoring across North America.
- Furthermore, increasingly strict FDA pharmacovigilance requirements and expanding investments in AI, cloud computing, and real-world evidence analytics are contributing to the swift adoption of intelligent drug safety and regulatory compliance applications throughout the region.
- These factors are driving innovation, regulatory compliance, and proactively managing the safety of drugs, reinforcing North America's position as a leader in AI-driven pharmacovigilance.
AI in Pharmacovigilance Market Ecosystem
The global AI in pharmacovigilance market is moderately consolidated, with leading companies including IQVIA, Oracle Corporation, Accenture, Cognizant Technology Solutions and ArisGlobal holding significant market positions through advanced artificial intelligence, machine learning, natural language processing, cloud computing, and real-world data analytics.
These firms use integrated digital safety platforms, worldwide regulatory experience, and scalable cloud infrastructures to increase pharmacovigilance operations, improve regulatory compliance, and speed up adverse event management across pharmaceutical and biotechnology organizations.
Market leaders are actively creating specialized AI-enabled solutions, such as automated case intake, intelligent medical coding, AI-driven signal identification, literature screening, and predictive safety analytics, to minimize human labor and improve drug safety decision-making. Agentic AI, generative AI, and natural language processing technologies accelerate the processing of safety situations while enhancing data quality and regulatory reporting accuracy.
The continued evolution of these capabilities is catalyzing the use of AI in pharmacovigilance, enhancing drug safety results, regulatory compliance, and operational efficiency, and ensuring continued growth in the AI market.
Recent Development and Strategic Overview:
- In September 2025, Oracle enhanced its Safety One Platform by integrating Oracle Real-World Data, Health Data Intelligence, and OCI AI Services to strengthen precision pharmacovigilance through predictive analytics, connected safety intelligence, and AI-enabled regulatory decision support.
- In June 2025, IQVIA launched NVIDIA-powered AI agents for life sciences to automate literature review, clinical data review, and workflow coordination, accelerating pharmacovigilance insights, improving operational efficiency, and enhancing AI-driven drug safety and clinical development processes.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 0.4 Bn |
|
Market Forecast Value in 2035 |
USD 1.9 Bn |
|
Growth Rate (CAGR) |
17.1% |
|
Forecast Period |
2026 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|||||
AI in Pharmacovigilance Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
AI in Pharmacovigilance Market, By Component |
|
|
AI in Pharmacovigilance Market, By Technology |
|
|
AI in Pharmacovigilance Market, By Deployment Mode |
|
|
AI in Pharmacovigilance Market, By Process Stage |
|
|
AI in Pharmacovigilance Market, By Application |
|
|
AI in Pharmacovigilance Market, By End-users |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global AI in Pharmacovigilance Market Outlook
- 2.1.1. AI in Pharmacovigilance Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global AI in Pharmacovigilance Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. AI adoption for automated adverse event detection and signal management
- 4.1.1.2. Rising real-world data volume driving advanced pharmacovigilance analytics
- 4.1.1.3. Regulatory focus on faster drug safety monitoring and compliance
- 4.1.2. Restraints
- 4.1.2.1. Data privacy and regulatory compliance challenges
- 4.1.2.2. Limited standardized datasets reducing AI model accuracy
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global AI in Pharmacovigilance Market Demand
- 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
- 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
- 4.7.2.1. Y-o-Y Growth Trends
- 4.7.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global AI in Pharmacovigilance Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
- 6.2.1. Software
- 6.2.1.1. Standalone Software
- 6.2.1.2. Integrated/Embedded Software
- 6.2.2. Services
- 6.2.2.1. Professional Services
- 6.2.2.1.1. Consulting
- 6.2.2.1.2. Implementation & Integration
- 6.2.2.1.3. Training & Education
- 6.2.2.2. Managed Services
- 6.2.2.1. Professional Services
- 6.2.1. Software
- 7. Global AI in Pharmacovigilance Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
- 7.2.1. Machine Learning
- 7.2.2. Natural Language Processing (NLP)
- 7.2.3. Deep Learning
- 7.2.4. Robotic Process Automation (RPA)
- 7.2.5. Computer Vision
- 7.2.6. Predictive Analytics
- 7.2.7. Others
- 8. Global AI in Pharmacovigilance Market Analysis, by Deployment Mode
- 8.1. Key Segment Analysis
- 8.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
- 8.2.1. Cloud-Based
- 8.2.2. On-Premise
- 8.2.3. Hybrid
- 9. Global AI in Pharmacovigilance Market Analysis, by Process Stage
- 9.1. Key Segment Analysis
- 9.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Process Stage, 2021-2035
- 9.2.1. Case Intake & Triage
- 9.2.2. Case Data Entry & Processing
- 9.2.3. Medical Review & Assessment
- 9.2.4. Signal Detection & Validation
- 9.2.5. Regulatory Submission & Reporting
- 9.2.6. Quality Control & Audit
- 10. Global AI in Pharmacovigilance Market Analysis, by Application
- 10.1. Key Segment Analysis
- 10.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
- 10.2.1. Adverse Event Detection and Reporting
- 10.2.2. Case Processing and Triage
- 10.2.3. Signal Detection and Management
- 10.2.4. Literature Monitoring & Screening
- 10.2.5. Regulatory Reporting & Submission
- 10.2.6. Medical Coding
- 10.2.7. Data Mining and Analytics
- 10.2.8. Risk Management & Benefit-Risk Assessment
- 10.2.9. Social Media & Real-World Data Monitoring
- 10.2.10. Other Applications
- 11. Global AI in Pharmacovigilance Market Analysis, by End-users
- 11.1. Key Segment Analysis
- 11.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
- 11.2.1. Pharmaceutical Companies
- 11.2.2. Biotechnology Companies
- 11.2.3. Contract Research Organizations (CROs)
- 11.2.4. Medical Device Companies
- 11.2.5. Regulatory Authorities
- 11.2.6. Academic and Research Institutes
- 11.2.7. Others
- 12. Global AI in Pharmacovigilance Market Analysis, by Region
- 12.1. Key Findings
- 12.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 12.2.1. North America
- 12.2.2. Europe
- 12.2.3. Asia Pacific
- 12.2.4. Middle East
- 12.2.5. Africa
- 12.2.6. South America
- 13. North America AI in Pharmacovigilance Market Analysis
- 13.1. Key Segment Analysis
- 13.2. Regional Snapshot
- 13.3. North America AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 13.3.1. Component
- 13.3.2. Technology
- 13.3.3. Deployment Mode
- 13.3.4. Process Stage
- 13.3.5. Application
- 13.3.6. End-users
- 13.3.7. Country
- 13.3.7.1. USA
- 13.3.7.2. Canada
- 13.3.7.3. Mexico
- 13.4. USA AI in Pharmacovigilance Market
- 13.4.1. Country Segmental Analysis
- 13.4.2. Component
- 13.4.3. Technology
- 13.4.4. Deployment Mode
- 13.4.5. Process Stage
- 13.4.6. Application
- 13.4.7. End-users
- 13.5. Canada AI in Pharmacovigilance Market
- 13.5.1. Country Segmental Analysis
- 13.5.2. Component
- 13.5.3. Technology
- 13.5.4. Deployment Mode
- 13.5.5. Process Stage
- 13.5.6. Application
- 13.5.7. End-users
- 13.6. Mexico AI in Pharmacovigilance Market
- 13.6.1. Country Segmental Analysis
- 13.6.2. Component
- 13.6.3. Technology
- 13.6.4. Deployment Mode
- 13.6.5. Process Stage
- 13.6.6. Application
- 13.6.7. End-users
- 14. Europe AI in Pharmacovigilance Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. Europe AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 14.3.1. Component
- 14.3.2. Technology
- 14.3.3. Deployment Mode
- 14.3.4. Process Stage
- 14.3.5. Application
- 14.3.6. End-users
- 14.3.7. Country
- 14.3.7.1. Germany
- 14.3.7.2. United Kingdom
- 14.3.7.3. France
- 14.3.7.4. Italy
- 14.3.7.5. Spain
- 14.3.7.6. Netherlands
- 14.3.7.7. Nordic Countries
- 14.3.7.8. Poland
- 14.3.7.9. Russia & CIS
- 14.3.7.10. Rest of Europe
- 14.4. Germany AI in Pharmacovigilance Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Component
- 14.4.3. Technology
- 14.4.4. Deployment Mode
- 14.4.5. Process Stage
- 14.4.6. Application
- 14.4.7. End-users
- 14.5. United Kingdom AI in Pharmacovigilance Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Component
- 14.5.3. Technology
- 14.5.4. Deployment Mode
- 14.5.5. Process Stage
- 14.5.6. Application
- 14.5.7. End-users
- 14.6. France AI in Pharmacovigilance Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Component
- 14.6.3. Technology
- 14.6.4. Deployment Mode
- 14.6.5. Process Stage
- 14.6.6. Application
- 14.6.7. End-users
- 14.7. Italy AI in Pharmacovigilance Market
- 14.7.1. Country Segmental Analysis
- 14.7.2. Component
- 14.7.3. Technology
- 14.7.4. Deployment Mode
- 14.7.5. Process Stage
- 14.7.6. Application
- 14.7.7. End-users
- 14.8. Spain AI in Pharmacovigilance Market
- 14.8.1. Country Segmental Analysis
- 14.8.2. Component
- 14.8.3. Technology
- 14.8.4. Deployment Mode
- 14.8.5. Process Stage
- 14.8.6. Application
- 14.8.7. End-users
- 14.9. Netherlands AI in Pharmacovigilance Market
- 14.9.1. Country Segmental Analysis
- 14.9.2. Component
- 14.9.3. Technology
- 14.9.4. Deployment Mode
- 14.9.5. Process Stage
- 14.9.6. Application
- 14.9.7. End-users
- 14.10. Nordic Countries AI in Pharmacovigilance Market
- 14.10.1. Country Segmental Analysis
- 14.10.2. Component
- 14.10.3. Technology
- 14.10.4. Deployment Mode
- 14.10.5. Process Stage
- 14.10.6. Application
- 14.10.7. End-users
- 14.11. Poland AI in Pharmacovigilance Market
- 14.11.1. Country Segmental Analysis
- 14.11.2. Component
- 14.11.3. Technology
- 14.11.4. Deployment Mode
- 14.11.5. Process Stage
- 14.11.6. Application
- 14.11.7. End-users
- 14.12. Russia & CIS AI in Pharmacovigilance Market
- 14.12.1. Country Segmental Analysis
- 14.12.2. Component
- 14.12.3. Technology
- 14.12.4. Deployment Mode
- 14.12.5. Process Stage
- 14.12.6. Application
- 14.12.7. End-users
- 14.13. Rest of Europe AI in Pharmacovigilance Market
- 14.13.1. Country Segmental Analysis
- 14.13.2. Component
- 14.13.3. Technology
- 14.13.4. Deployment Mode
- 14.13.5. Process Stage
- 14.13.6. Application
- 14.13.7. End-users
- 15. Asia Pacific AI in Pharmacovigilance Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Asia Pacific AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 15.3.1. Component
- 15.3.2. Technology
- 15.3.3. Deployment Mode
- 15.3.4. Process Stage
- 15.3.5. Application
- 15.3.6. End-users
- 15.3.7. Country
- 15.3.7.1. China
- 15.3.7.2. India
- 15.3.7.3. Japan
- 15.3.7.4. South Korea
- 15.3.7.5. Australia and New Zealand
- 15.3.7.6. Indonesia
- 15.3.7.7. Malaysia
- 15.3.7.8. Thailand
- 15.3.7.9. Vietnam
- 15.3.7.10. Rest of Asia Pacific
- 15.4. China AI in Pharmacovigilance Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Component
- 15.4.3. Technology
- 15.4.4. Deployment Mode
- 15.4.5. Process Stage
- 15.4.6. Application
- 15.4.7. End-users
- 15.5. India AI in Pharmacovigilance Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Component
- 15.5.3. Technology
- 15.5.4. Deployment Mode
- 15.5.5. Process Stage
- 15.5.6. Application
- 15.5.7. End-users
- 15.6. Japan AI in Pharmacovigilance Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Component
- 15.6.3. Technology
- 15.6.4. Deployment Mode
- 15.6.5. Process Stage
- 15.6.6. Application
- 15.6.7. End-users
- 15.7. South Korea AI in Pharmacovigilance Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Component
- 15.7.3. Technology
- 15.7.4. Deployment Mode
- 15.7.5. Process Stage
- 15.7.6. Application
- 15.7.7. End-users
- 15.8. Australia and New Zealand AI in Pharmacovigilance Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Component
- 15.8.3. Technology
- 15.8.4. Deployment Mode
- 15.8.5. Process Stage
- 15.8.6. Application
- 15.8.7. End-users
- 15.9. Indonesia AI in Pharmacovigilance Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Component
- 15.9.3. Technology
- 15.9.4. Deployment Mode
- 15.9.5. Process Stage
- 15.9.6. Application
- 15.9.7. End-users
- 15.10. Malaysia AI in Pharmacovigilance Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Component
- 15.10.3. Technology
- 15.10.4. Deployment Mode
- 15.10.5. Process Stage
- 15.10.6. Application
- 15.10.7. End-users
- 15.11. Thailand AI in Pharmacovigilance Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Component
- 15.11.3. Technology
- 15.11.4. Deployment Mode
- 15.11.5. Process Stage
- 15.11.6. Application
- 15.11.7. End-users
- 15.12. Vietnam AI in Pharmacovigilance Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Component
- 15.12.3. Technology
- 15.12.4. Deployment Mode
- 15.12.5. Process Stage
- 15.12.6. Application
- 15.12.7. End-users
- 15.13. Rest of Asia Pacific AI in Pharmacovigilance Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Component
- 15.13.3. Technology
- 15.13.4. Deployment Mode
- 15.13.5. Process Stage
- 15.13.6. Application
- 15.13.7. End-users
- 16. Middle East AI in Pharmacovigilance Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Middle East AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Component
- 16.3.2. Technology
- 16.3.3. Deployment Mode
- 16.3.4. Process Stage
- 16.3.5. Application
- 16.3.6. End-users
- 16.3.7. Country
- 16.3.7.1. Turkey
- 16.3.7.2. UAE
- 16.3.7.3. Saudi Arabia
- 16.3.7.4. Israel
- 16.3.7.5. Rest of Middle East
- 16.4. Turkey AI in Pharmacovigilance Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Component
- 16.4.3. Technology
- 16.4.4. Deployment Mode
- 16.4.5. Process Stage
- 16.4.6. Application
- 16.4.7. End-users
- 16.5. UAE AI in Pharmacovigilance Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Component
- 16.5.3. Technology
- 16.5.4. Deployment Mode
- 16.5.5. Process Stage
- 16.5.6. Application
- 16.5.7. End-users
- 16.6. Saudi Arabia AI in Pharmacovigilance Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Component
- 16.6.3. Technology
- 16.6.4. Deployment Mode
- 16.6.5. Process Stage
- 16.6.6. Application
- 16.6.7. End-users
- 16.7. Israel AI in Pharmacovigilance Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Component
- 16.7.3. Technology
- 16.7.4. Deployment Mode
- 16.7.5. Process Stage
- 16.7.6. Application
- 16.7.7. End-users
- 16.8. Rest of Middle East AI in Pharmacovigilance Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Component
- 16.8.3. Technology
- 16.8.4. Deployment Mode
- 16.8.5. Process Stage
- 16.8.6. Application
- 16.8.7. End-users
- 17. Africa AI in Pharmacovigilance Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Africa AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Component
- 17.3.2. Technology
- 17.3.3. Deployment Mode
- 17.3.4. Process Stage
- 17.3.5. Application
- 17.3.6. End-users
- 17.3.7. Country
- 17.3.7.1. South Africa
- 17.3.7.2. Egypt
- 17.3.7.3. Nigeria
- 17.3.7.4. Algeria
- 17.3.7.5. Rest of Africa
- 17.4. South Africa AI in Pharmacovigilance Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Component
- 17.4.3. Technology
- 17.4.4. Deployment Mode
- 17.4.5. Process Stage
- 17.4.6. Application
- 17.4.7. End-users
- 17.5. Egypt AI in Pharmacovigilance Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Component
- 17.5.3. Technology
- 17.5.4. Deployment Mode
- 17.5.5. Process Stage
- 17.5.6. Application
- 17.5.7. End-users
- 17.6. Nigeria AI in Pharmacovigilance Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Component
- 17.6.3. Technology
- 17.6.4. Deployment Mode
- 17.6.5. Process Stage
- 17.6.6. Application
- 17.6.7. End-users
- 17.7. Algeria AI in Pharmacovigilance Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Component
- 17.7.3. Technology
- 17.7.4. Deployment Mode
- 17.7.5. Process Stage
- 17.7.6. Application
- 17.7.7. End-users
- 17.8. Rest of Africa AI in Pharmacovigilance Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Component
- 17.8.3. Technology
- 17.8.4. Deployment Mode
- 17.8.5. Process Stage
- 17.8.6. Application
- 17.8.7. End-users
- 18. South America AI in Pharmacovigilance Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. South America AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Component
- 18.3.2. Technology
- 18.3.3. Deployment Mode
- 18.3.4. Process Stage
- 18.3.5. Application
- 18.3.6. End-users
- 18.3.7. Country
- 18.3.7.1. Brazil
- 18.3.7.2. Argentina
- 18.3.7.3. Rest of South America
- 18.4. Brazil AI in Pharmacovigilance Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Component
- 18.4.3. Technology
- 18.4.4. Deployment Mode
- 18.4.5. Process Stage
- 18.4.6. Application
- 18.4.7. End-users
- 18.5. Argentina AI in Pharmacovigilance Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Component
- 18.5.3. Technology
- 18.5.4. Deployment Mode
- 18.5.5. Process Stage
- 18.5.6. Application
- 18.5.7. End-users
- 18.6. Rest of South America AI in Pharmacovigilance Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Component
- 18.6.3. Technology
- 18.6.4. Deployment Mode
- 18.6.5. Process Stage
- 18.6.6. Application
- 18.6.7. End-users
- 19. Key Players/ Company Profile
- 19.1. Cognizant Technology Solutions
- 19.1.1. Company Details/ Overview
- 19.1.2. Company Financials
- 19.1.3. Key Customers and Competitors
- 19.1.4. Business/ Industry Portfolio
- 19.1.5. Product Portfolio/ Specification Details
- 19.1.6. Pricing Data
- 19.1.7. Strategic Overview
- 19.1.8. Recent Developments
- 19.2. Accenture
- 19.3. ArisGlobal
- 19.4. Capgemini SE
- 19.5. ICON plc
- 19.6. IQVIA
- 19.7. Oracle Corporation
- 19.8. Parexel International Corporation
- 19.9. Tata Consultancy Services (TCS)
- 19.10. Wipro Limited
- 19.11. Other Key Players
- 19.1. Cognizant Technology Solutions
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation